Mitrix Bio

Mitrix Bio is a private U.S. regenerative medicine and longevity biotech developing mitochondrial transplantation therapies for age-related and mitochondrial dysfunction-associated diseases. The company is building a platform to grow young mitochondria in bioreactors at scale and package them in extracellular vesicle-like carriers it calls "Mitlets" to support tissue-targeted delivery. Its approach is aimed at restoring cellular energetics and addressing degeneration linked to aging rather than pursuing a single conventional drug target. Mitrix Bio appears to be platform-oriented and preclinical, with publicly described work spanning immune, retinal, brain, and skin applications as well as broader age-related disorders. The company is headquartered in Pleasanton, California and is backed by investors including R42 Capital and LongevityTech Fund.